Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus lenvatinib versus lenvatinib alone as first-line treatment for advanced hepatocellular carcinoma
CTR20210634Phase 3Active
- Sponsor
- Suzhou Union Biopharm
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Suzhou Union Biopharm. Started Jun 2020; status: active.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20210634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210634.